 Connection
David Camidge to Lung Diseases, Interstitial
This is a "connection" page, showing publications David Camidge has written about Lung Diseases, Interstitial.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.696 |
|
|
|
-
Powell CA, Modi S, Iwata H, Takahashi S, Smit EF, Siena S, Chang DY, Macpherson E, Qin A, Singh J, Taitt C, Shire N, Camidge DR. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open. 2022 08; 7(4):100554.
Score: 0.600
-
Noonan SA, Sachs PB, Camidge DR. Transient Asymptomatic Pulmonary Opacities Occurring during Osimertinib Treatment. J Thorac Oncol. 2016 12; 11(12):2253-2258.
Score: 0.398
-
Browning ET, Huckleberry JM, Barrow WB, Restauri NL, Kemme DJ, Cool CD, Weyant MJ, Franklin WA, Camidge DR. Downstaging of Non-Small-Cell Lung Cancer Through Identification of Reversible Drug Toxicity. J Clin Oncol. 2016 Jan 10; 34(2):e6-8.
Score: 0.338
-
Erickson TM, Koeppe JR, Miller YE, Stuart RW, Camidge DR. Bronchioloalveolar carcinoma presenting as chronic progressive pulmonary infiltrates in a woman with HIV: a diagnosis worth making. J Thorac Oncol. 2008 Nov; 3(11):1353-5.
Score: 0.231
-
Hackshaw MD, Danysh HE, Singh J, Ritchey ME, Ladner A, Taitt C, Camidge DR, Iwata H, Powell CA. Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2020 Aug; 183(1):23-39.
Score: 0.129
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|